scholarly journals Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study

2020 ◽  
Vol 11 (6) ◽  
pp. 1612-1622
Author(s):  
Tomoe Kinoshita ◽  
Masashi Shimoda ◽  
Koji Nakashima ◽  
Yoshiro Fushimi ◽  
Yurie Hirata ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Active Control ◽  
Fatty Liver Disease ◽  
Open Label ◽  
Alcoholic Fatty Liver ◽  
Glucose Lowering ◽  
Alcoholic Fatty Liver Disease ◽  
Control Study

Dapagliflozin reduces hepatic and visceral fat in type‐2 diabetes patients with non‐alcoholic fatty liver disease

2021 ◽  
Author(s):  
Susrichit Phrueksotsai ◽  
Kanokwan Pinyopornpanish ◽  
Juntima Euathrongchit ◽  
Apinya Leerapun ◽  
Arintaya Phrommintikul ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Visceral Fat ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Diabetes Patients

scholarly journals Non‐alcoholic fatty liver disease in type 2 diabetes – A specific entity?

2021 ◽  
Vol 41 (S1) ◽  
pp. 105-111
Author(s):  
Benjamin Schröder ◽  
Sabine Kahl ◽  
Michael Roden
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document